Please use this identifier to cite or link to this item:
|Title:||The Future of Radioligand Therapy: α, β, or Both?|
|Authors:||HABERKORN UWE; GIESEL FREDERIK; MORGENSTERN ALFRED; KRATOCHWIL CLEMENS|
|Citation:||JOURNAL OF NUCLEAR MEDICINE vol. 58 no. 7 p. 1017-1018|
|Publisher:||SOC NUCLEAR MEDICINE INC|
|Type:||Articles in periodicals and books|
|Abstract:||Endoradiotherapy approaches are experiencing growing interest with the increase in the number of carrier molecules becoming available for different targets. The cross-fire effect has been described as an important mechanism for the efficacy of radioligand therapies by particle-induced destruction of multiple cells in the neighborhood of a tracer-accumulating cell, which at least partially compensates for the heterogeneity seen in malignant tumors. This is in contrast to nonradioactive targeting treatment, in which usually only the cells binding the therapeutic molecule are destroyed (one hit, one kill). Therapeutic effects are further enhanced by the radiation-induced bystander effect (RIBE). RIBE describes a situation in which cells that are not directly exposed to the ionizing radiation, but are in the neighborhood of exposed cells, behave as if they have been exposed (Fig. 1): they die or show chromosomal instabilities or other abnormalities. Although the exact mechanism of RIBE is not fully understood, there is evidence that stress signal factors transmit information from irradiated cells to neighboring cells.|
|JRC Directorate:||Nuclear Safety and Security|
Files in This Item:
There are no files associated with this item.
Items in repository are protected by copyright, with all rights reserved, unless otherwise indicated.